Biodesix, Inc. (NASDAQ:BDSX) CFO Robin Harper Cowie Sells 24,664 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) CFO Robin Harper Cowie sold 24,664 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $22,690.88. Following the transaction, the chief financial officer now directly owns 246,460 shares in the company, valued at $226,743.20. The trade was a 9.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Biodesix Trading Down 1.1 %

Shares of NASDAQ BDSX opened at $0.94 on Thursday. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. The stock has a market capitalization of $136.74 million, a P/E ratio of -2.41 and a beta of 1.06. Biodesix, Inc. has a 1-year low of $0.86 and a 1-year high of $2.04. The business has a fifty day moving average price of $1.25 and a 200 day moving average price of $1.49.

Institutional Investors Weigh In On Biodesix

A number of hedge funds have recently made changes to their positions in BDSX. Barclays PLC lifted its stake in shares of Biodesix by 1,140.5% during the 3rd quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after purchasing an additional 21,179 shares during the last quarter. HighTower Advisors LLC lifted its stake in shares of Biodesix by 17.1% during the 4th quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock worth $236,000 after purchasing an additional 22,500 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Biodesix during the 3rd quarter worth $262,000. Stephens Inc. AR purchased a new stake in shares of Biodesix during the 4th quarter worth $303,000. Finally, Geode Capital Management LLC lifted its stake in shares of Biodesix by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock worth $1,266,000 after purchasing an additional 22,623 shares during the last quarter. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.